Page 19 - 《中国药房》2024年3期
P. 19
2017,83(10):2195-2204. tumor[J]. Chin J Gastrointest Surg,2019,22(9):848-855.
[53] ZHANG Y J,QIANG S P,YU Z,et al. LC-MS-MS deter‐ [62] WIDMER N,DECOSTERD L A,CSAJKA C,et al. Ima‐
mination of imatinib and N-desmethyl imatinib in human tinib plasma levels:correlation with clinical benefit in
plasma[J]. J Chromatogr Sci,2014,52(4):344-350. GIST patients[J]. Br J Cancer,2010,102(7):1198-1199.
[54] MIURA M,TAKAHASHI N,SAWADA K I. Quantitative [63] DELBALDO C, CHATELUT E, RÉ M, et al.
determination of imatinib in human plasma with high- Pharmacokinetic-pharmacodynamic relationships of ima‐
performance liquid chromatography and ultraviolet detec‐ tinib and its main metabolite in patients with advanced
tion[J]. J Chromatogr Sci,2011,49(5):412-415. gastrointestinal stromal tumors[J]. Clin Cancer Res,2006,
[55] 董馨蔚,蒋刚,马松涛,等. 二维液相色谱法同时测定人 12(20 Pt 1):6073-6078.
血浆中伊马替尼及其代谢产物浓度的方法学研究[J]. 肿 [64] WANG Q,JIANG Z P,YU E Q,et al. Population pharma‐
瘤预防与治疗,2021,34(10):918-925. cokinetic and pharmacogenetics of imatinib in Chinese pa‐
DONG X W,JIANG G,MA S T,et al. Simultaneous de‐ tients with chronic myeloid leukemia[J]. Pharmacogeno-
termination of imatinib mesylate and its metabolites in hu‐ mics,2019,20(4):251-260.
man plasma by two-dimensional liquid chromatography:a [65] GSCHWIND H P,PFAAR U,WALDMEIER F,et al. Me‐
methodological study[J]. J Cancer Contr Treat,2021,34 tabolism and disposition of imatinib mesylate in healthy
(10):918-925. volunteers[J]. Drug Metab Dispos,2005,33(10):1503-
[56] 孔滢,刘红,彭洪薇,等. 二维液相色谱法同时测定人血 1512.
浆中伊马替尼及去甲伊马替尼药物浓度及临床应用[J]. [66] 中国药学会医院药学专业委员会. 治疗药物监测结果解
中国现代应用药学,2022,39(17):2229-2235. 读专家共识[J]. 中国医院药学杂志,2020,40(23):2389-
KONG Y,LIU H,PENG H W,et al. Simultaneous deter‐ 2395.
mination of imatinib and N-desmethyl imatinib in human Professional Committee of Hospital Pharmacy,Chinese
plasma by two-dimensional liquid chromatography and its Pharmaceutical Association. The expert consensus on the
clinical application[J]. Chin J Mod Appl Pharm,2022,39 interpretation of therapeutic drug monitoring[J]. Chin J
(17):2229-2235. Hosp Pharm,2020,40(23):2389-2395.
[57] ZHOU Y,LAI J L,QIU F,et al. Development and valida‐ [67] GOTTA V,WIDMER N,MONTEMURRO M,et al.
tion of an HPLC-UV method for routine trough plasma Therapeutic drug monitoring of imatinib:Bayesian and al‐
concentration monitoring of imatinib in Chinese patients ternative methods to predict trough levels[J]. Clin Pharma‐
with gastrointestinal stromal tumor[J]. J Chin Pharm Sci, cokinet,2012,51(3):187-201.
2020,29(9):637-648. [68] JANSSEN J M,DORLO T P C,BEIJNEN J H,et al.
[58] 张玉,缪丽燕. 胃肠间质瘤靶向药物的治疗药物监测中 Evaluation of extrapolation methods to predict trough con‐
国专家共识[J]. 中国医院药学杂志,2021,41(20):2041- centrations to guide therapeutic drug monitoring of oral
2049. anticancer drugs[J]. Ther Drug Monit,2020,42(4):
ZHANG Y,MIAO L Y. Chinese expert consensus on 532-539.
therapeutic drug monitoring of targeted drugs for gastroin‐ [69] ZHOU Y,WU X Y,LI J,et al. Clinical and economic
testinal stromal tumor[J]. Chin J Hosp Pharm,2021,41 benefits of a pharmacist in a multidisciplinary team for
(20):2041-2049. Chinese outpatients with gastrointestinal stromal tumors
[59] DEMETRI G D,WANG Y F,WEHRLE E,et al. Imatinib [J]. J Chin Pharm Sci,2021,30(7):598-605.
plasma levels are correlated with clinical benefit in pa‐ [70] 张威,张宇晴,陆进,等. 医疗机构药事管理与药学服务
tients with unresectable/metastatic gastrointestinal stromal 团体标准体系设计及构建[J]. 医药导报,2023,42(10):
tumors[J]. J Clin Oncol,2009,27(19):3141-3147. 1455-1459.
[60] TERANISHI R,TAKAHASHI T,NISHIDA T,et al. ZHANG W,ZHANG Y Q,LU J,et al. Design and con‐
Plasma trough concentration of imatinib and its effect on struction of group standard system framework for phar‐
therapeutic efficacy and adverse events in Japanese pa‐ macy administration and pharmacy practice in healthcare
tients with GIST[J]. Int J Clin Oncol,2023,28(5): institutions[J]. Her Med,2023,42(10):1455-1459.
680-687. [71] MORISKY D E,ANG A,KROUSEL-WOOD M,et al.
[61] WAN W Z,ZHANG P,ZENG X Y,et al. Analysis of ima‐ Predictive validity of a medication adherence measure in
tinib trough concentration at steady state in adjuvant an outpatient setting[J]. J Clin Hypertens,2008,10(5):
therapy of patients with high risk gastrointestinal stromal 348-354.
中国药房 2024年第35卷第3期 China Pharmacy 2024 Vol. 35 No. 3 · 269 ·